Waring_2015_J.Alzheimers.Dis_47_137

Reference

Title : APOE-varepsilon4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease - Waring_2015_J.Alzheimers.Dis_47_137
Author(s) : Waring JF , Tang Q , Robieson WZ , King DP , Das U , Dubow J , Dutta S , Marek GJ , Gault LM
Ref : J Alzheimers Dis , 47 :137 , 2015
Abstract :

BACKGROUND: Previous studies have investigated associations between apolipoprotein E (APOE)-varepsilon4 allele status and acetylcholinesterase inhibitor treatment response in patients with Alzheimer's disease. The ability to draw definitive conclusions regarding the effect of APOE-varepsilon4 genotype on treatment response has been hindered by inconsistent results among studies and methodological limitations that restrict interpretation of study findings. OBJECTIVE: To determine whether APOE-varepsilon4 carrier status influences the magnitude of change in 13-item Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) score associated with acetylcholinesterase inhibitor treatment (i.e., donepezil).
METHODS: Analyses were performed using pooled data from the donepezil and placebo treatment arms of three consecutive, similarly designed, 12-week, multi-national, randomized clinical studies that enrolled patients with mild-to-moderate Alzheimer's disease. Correlations between APOE-varepsilon4 carrier status and ADAS-cog scores were evaluated using analysis of covariance.
RESULTS: No appreciable interaction between donepezil response and APOE-varepsilon4 carrier status or copy number was detected. Both carriers and non-carriers of APOE-varepsilon4 who received donepezil experienced significant improvements from baseline in ADAS-cog score versus placebo (p < 0.05). Change from baseline to final observation in the donepezil treatment group was - 2.95 for APOE-varepsilon4 carriers and - 4.09 for non-carriers (p = 0.23). In contrast, non-carriers of APOE-varepsilon4 in the placebo treatment group exhibited a greater improvement from baseline versus carriers (-2.38 versus - 0.60, p = 0.05). CONCLUSION: Within this population, APOE genotype had no statistically significant effect on cognitive response to donepezil treatment; however, APOE-varepsilon4 allele status was associated with a difference in the magnitude of the change in ADAS-cog of placebo-treated patients.

PubMedSearch : Waring_2015_J.Alzheimers.Dis_47_137
PubMedID: 26402762

Related information

Citations formats

Waring JF, Tang Q, Robieson WZ, King DP, Das U, Dubow J, Dutta S, Marek GJ, Gault LM (2015)
APOE-varepsilon4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease
J Alzheimers Dis 47 :137

Waring JF, Tang Q, Robieson WZ, King DP, Das U, Dubow J, Dutta S, Marek GJ, Gault LM (2015)
J Alzheimers Dis 47 :137